346 related articles for article (PubMed ID: 15036678)
1. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
2. [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention].
Altarac S
Lijec Vjesn; 2006; 128(7-8):233-7. PubMed ID: 17087140
[TBL] [Abstract][Full Text] [Related]
3. Prostate size influences the outcome after presenting with acute urinary retention.
McNeill AS; Rizvi S; Byrne DJ
BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
[TBL] [Abstract][Full Text] [Related]
4. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
5. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
7. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
8. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
9. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
10. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
[TBL] [Abstract][Full Text] [Related]
11. Acute urinary retention: medical management and the identification of risk factors for prevention.
Khastgir J; Khan A; Speakman M
Nat Clin Pract Urol; 2007 Aug; 4(8):422-31. PubMed ID: 17673913
[TBL] [Abstract][Full Text] [Related]
12. Does acute urinary retention respond to alpha-blockers alone?
McNeill SA
Eur Urol; 2001 Mar; 39 Suppl 6():7-12. PubMed ID: 11306895
[TBL] [Abstract][Full Text] [Related]
13. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
Lucas MG; Stephenson TP; Nargund V
BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
16. Results of treatment with tamsulosin in men with acute urinary retention.
Kim HL; Kim JC; Benson DA; Bales GT; Gerber GS
Tech Urol; 2001 Dec; 7(4):256-60. PubMed ID: 11763483
[TBL] [Abstract][Full Text] [Related]
17. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
18. Management outcome of acute urinary retention: model of prediction.
Daly P; Connolly S; Rogers E; Sweeney P
Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357
[TBL] [Abstract][Full Text] [Related]
19. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
20. Definition of at-risk patients: dynamic variables.
Emberton M
BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
